43
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Gymnemic Acid-Rich Fraction from Gymnema Sylvestre Leaves Ameliorates Post Prandial Hyperglycaemia in In-vitro and In-vivo Studies

, , &
Pages 32-41 | Received 22 Jun 2020, Accepted 24 Feb 2021, Published online: 04 Mar 2021
 

Abstract

Gymnemic acids are triterpenoid glycosides with gymnemagenin as common aglycone found in Gymnema sylvestre (Gurmar). G. sylvestre is often used in herbal formulations because of its beneficial actions in diabetes, hyperlipidemia, and gastric problems. The purpose of the present study is to evaluate gymnemic acid-rich fraction of G. sylvestre in in-vitro and in-vivo model to control postprandial hyperglycemia. The gymnemic acid-rich fraction of G. sylvestre (GARF) was prepared by ultrasonic-assisted extraction using methanol-water (81:19 v/v) at a temperature of 49°C for 50 min using a solid-to-solvent ratio of 1:12.5 g/ml and gymnemic acid content was determined by validated High-performance thin-layer chromatography (HPTLC) densitometric method. The GARF effect was evaluated in the in-vitro model on α-amylase and α-glucosidase enzymes, while the antihyperglycemic effect was studied in carbohydrate-challenged and diabetic rats induced by Streptozotocin (STZ). In vitro studies show that GARF produces dose-dependent enzyme inhibition with IC50 values of 4.34 ± 0.81 mg/ml and 8.78 ± 1.22 mg/ml, respectively. In-vivo studies of normal and diabetic rats showed that GARF treatment (200 mg/kg b.w., p.o.), causes a significant (p < 0.01) blood glucose reduction effect in both models. The current study provides a scientific basis for the use of G. sylvestre in the management of diabetes mellitus.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.